APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hemophilia Drugs Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchHemophilia Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hemophilia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hemophilia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemophilia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemophilia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemophilia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemophilia Drugs market include Pfizer, Bayer, Swedish Orphan Biovitrum, Spark Therapeutics, Sangamo Biosciences, Octapharma, Grifols, F. Hoffmann-La Roche and Dimension Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hemophilia Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemophilia Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hemophilia Drugs market.

Hemophilia Drugs Segment by Company

Pfizer

Bayer

Swedish Orphan Biovitrum

Spark Therapeutics

Sangamo Biosciences

Octapharma

Grifols

F. Hoffmann-La Roche

Dimension Therapeutics

CSL Behring

Catalyst Biosciences

BioMarin

Baxalta

Alnylam Pharmaceuticals

Hemophilia Drugs Segment by Type

Von Willebrand Disease

Hemophilia A

Hemophilia B

Inhibitors

Hemophilia Drugs Segment by Application

Recombinant Therapies

Plasma-Derived Therapies

Hemophilia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemophilia Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hemophilia Drugs key companies, revenue, market share, and recent developments.

3. To split the Hemophilia Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hemophilia Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemophilia Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Hemophilia Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia Drugs industry.

Chapter 3: Detailed analysis of Hemophilia Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hemophilia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hemophilia Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemophilia Drugs Industry Trends Table 2. Hemophilia Drugs Industry Drivers Table 3. Hemophilia Drugs Industry Opportunities and Challenges Table 4. Hemophilia Drugs Industry Restraints Table 5. Global Hemophilia Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemophilia Drugs Revenue Share by Company (2021-2026) Table 7. Global Hemophilia Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hemophilia Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Hemophilia Drugs Company, Product Type & Application Table 10. Global Hemophilia Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Von Willebrand Disease Table 15. Significant Companies of Hemophilia A Table 16. Significant Companies of Hemophilia B Table 17. Significant Companies of Inhibitors Table 18. Global Hemophilia Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Hemophilia Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Hemophilia Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Hemophilia Drugs Sales Value Share by Type (2021-2026) Table 22. Global Hemophilia Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Recombinant Therapies Table 24. Significant Companies of Plasma-Derived Therapies Table 25. Global Hemophilia Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hemophilia Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Hemophilia Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Hemophilia Drugs Sales Value Share by Application (2021-2026) Table 29. Global Hemophilia Drugs Sales Value Share by Application (2027-2032) Table 30. Global Hemophilia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Hemophilia Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Hemophilia Drugs Sales Value Share by Region (2021-2026) Table 33. Global Hemophilia Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Hemophilia Drugs Sales Value Share by Region (2027-2032) Table 35. Global Hemophilia Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Hemophilia Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Hemophilia Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Hemophilia Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Hemophilia Drugs Sales Value Market Share by Country (2027-2032) Table 40. Pfizer Company Information Table 41. Pfizer Business Overview Table 42. Pfizer Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Pfizer Hemophilia Drugs Product Portfolio Table 44. Pfizer Recent Development Table 45. Bayer Company Information Table 46. Bayer Business Overview Table 47. Bayer Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Bayer Hemophilia Drugs Product Portfolio Table 49. Bayer Recent Development Table 50. Swedish Orphan Biovitrum Company Information Table 51. Swedish Orphan Biovitrum Business Overview Table 52. Swedish Orphan Biovitrum Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio Table 54. Swedish Orphan Biovitrum Recent Development Table 55. Spark Therapeutics Company Information Table 56. Spark Therapeutics Business Overview Table 57. Spark Therapeutics Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Spark Therapeutics Hemophilia Drugs Product Portfolio Table 59. Spark Therapeutics Recent Development Table 60. Sangamo Biosciences Company Information Table 61. Sangamo Biosciences Business Overview Table 62. Sangamo Biosciences Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sangamo Biosciences Hemophilia Drugs Product Portfolio Table 64. Sangamo Biosciences Recent Development Table 65. Octapharma Company Information Table 66. Octapharma Business Overview Table 67. Octapharma Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Octapharma Hemophilia Drugs Product Portfolio Table 69. Octapharma Recent Development Table 70. Grifols Company Information Table 71. Grifols Business Overview Table 72. Grifols Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Grifols Hemophilia Drugs Product Portfolio Table 74. Grifols Recent Development Table 75. F. Hoffmann-La Roche Company Information Table 76. F. Hoffmann-La Roche Business Overview Table 77. F. Hoffmann-La Roche Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio Table 79. F. Hoffmann-La Roche Recent Development Table 80. Dimension Therapeutics Company Information Table 81. Dimension Therapeutics Business Overview Table 82. Dimension Therapeutics Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Dimension Therapeutics Hemophilia Drugs Product Portfolio Table 84. Dimension Therapeutics Recent Development Table 85. CSL Behring Company Information Table 86. CSL Behring Business Overview Table 87. CSL Behring Hemophilia Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. CSL Behring Hemophilia Drugs Product Portfolio Table 89. CSL Behring Recent Development Table 90. Catalyst Biosciences Company Information Table 91. Catalyst Biosciences Business Overview Table 92. Catalyst Biosciences Hemophilia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Catalyst Biosciences Hemophilia Drugs Product Portfolio Table 94. Catalyst Biosciences Recent Development Table 95. BioMarin Company Information Table 96. BioMarin Business Overview Table 97. BioMarin Hemophilia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. BioMarin Hemophilia Drugs Product Portfolio Table 99. BioMarin Recent Development Table 100. Baxalta Company Information Table 101. Baxalta Business Overview Table 102. Baxalta Hemophilia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Baxalta Hemophilia Drugs Product Portfolio Table 104. Baxalta Recent Development Table 105. Alnylam Pharmaceuticals Company Information Table 106. Alnylam Pharmaceuticals Business Overview Table 107. Alnylam Pharmaceuticals Hemophilia Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio Table 109. Alnylam Pharmaceuticals Recent Development Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Hemophilia Drugs Product Image Figure 2. Global Hemophilia Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Von Willebrand Disease Image Figure 8. Hemophilia A Image Figure 9. Hemophilia B Image Figure 10. Inhibitors Image Figure 11. Global Hemophilia Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Hemophilia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Hemophilia Drugs Sales Value Share by Type (2021-2032) Figure 14. Recombinant Therapies Image Figure 15. Plasma-Derived Therapies Image Figure 16. Global Hemophilia Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Hemophilia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Hemophilia Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Hemophilia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Hemophilia Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Hemophilia Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Hemophilia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Hemophilia Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Hemophilia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Hemophilia Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Hemophilia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Hemophilia Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Hemophilia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Hemophilia Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Hemophilia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Hemophilia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Von Willebrand Disease
  • Hemophilia A
  • Hemophilia B
  • Inhibitors
Applications
  • Recombinant Therapies
  • Plasma-Derived Therapies
Companies covered
  • Pfizer
  • Bayer
  • Swedish Orphan Biovitrum
  • Spark Therapeutics
  • Sangamo Biosciences
  • Octapharma
  • Grifols
  • F. Hoffmann-La Roche
  • Dimension Therapeutics
  • CSL Behring
  • Catalyst Biosciences
  • BioMarin
  • Baxalta
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemophilia Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemophilia Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hemophilia Drugs Market Dynamics
  1. 2.1 Hemophilia Drugs Industry Trends
  2. 2.2 Hemophilia Drugs Industry Drivers
  3. 2.3 Hemophilia Drugs Industry Opportunities and Challenges
  4. 2.4 Hemophilia Drugs Industry Restraints
3 Hemophilia Drugs Market by Company
  1. 3.1 Global Hemophilia Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Hemophilia Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Hemophilia Drugs Company Ranking (2024-2026)
  4. 3.4 Global Hemophilia Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Hemophilia Drugs Company Product Type and Application
  6. 3.6 Global Hemophilia Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hemophilia Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hemophilia Drugs Market by Type
  1. 4.1 Hemophilia Drugs Type Introduction
  2. 4.1.1 Von Willebrand Disease
  3. 4.1.2 Hemophilia A
  4. 4.1.3 Hemophilia B
  5. 4.1.4 Inhibitors
  6. 4.2 Global Hemophilia Drugs Sales Value by Type
  7. 4.2.1 Global Hemophilia Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Hemophilia Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Hemophilia Drugs Sales Value Share by Type (2021-2032)
5 Hemophilia Drugs Market by Application
  1. 5.1 Hemophilia Drugs Application Introduction
  2. 5.1.1 Recombinant Therapies
  3. 5.1.2 Plasma-Derived Therapies
  4. 5.2 Global Hemophilia Drugs Sales Value by Application
  5. 5.2.1 Global Hemophilia Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hemophilia Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Hemophilia Drugs Sales Value Share by Application (2021-2032)
6 Hemophilia Drugs Regional Value Analysis
  1. 6.1 Global Hemophilia Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemophilia Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hemophilia Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hemophilia Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemophilia Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Hemophilia Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hemophilia Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Hemophilia Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hemophilia Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hemophilia Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hemophilia Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Hemophilia Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hemophilia Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hemophilia Drugs Sales Value Share by Country, 2025 VS 2032
7 Hemophilia Drugs Country-level Value Analysis
  1. 7.1 Global Hemophilia Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemophilia Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hemophilia Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hemophilia Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hemophilia Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hemophilia Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hemophilia Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Hemophilia Drugs Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Hemophilia Drugs Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Swedish Orphan Biovitrum
  14. 8.3.1 Swedish Orphan Biovitrum Company Information
  15. 8.3.2 Swedish Orphan Biovitrum Business Overview
  16. 8.3.3 Swedish Orphan Biovitrum Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
  18. 8.3.5 Swedish Orphan Biovitrum Recent Developments
  19. 8.4 Spark Therapeutics
  20. 8.4.1 Spark Therapeutics Company Information
  21. 8.4.2 Spark Therapeutics Business Overview
  22. 8.4.3 Spark Therapeutics Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
  24. 8.4.5 Spark Therapeutics Recent Developments
  25. 8.5 Sangamo Biosciences
  26. 8.5.1 Sangamo Biosciences Company Information
  27. 8.5.2 Sangamo Biosciences Business Overview
  28. 8.5.3 Sangamo Biosciences Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
  30. 8.5.5 Sangamo Biosciences Recent Developments
  31. 8.6 Octapharma
  32. 8.6.1 Octapharma Company Information
  33. 8.6.2 Octapharma Business Overview
  34. 8.6.3 Octapharma Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Octapharma Hemophilia Drugs Product Portfolio
  36. 8.6.5 Octapharma Recent Developments
  37. 8.7 Grifols
  38. 8.7.1 Grifols Company Information
  39. 8.7.2 Grifols Business Overview
  40. 8.7.3 Grifols Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Grifols Hemophilia Drugs Product Portfolio
  42. 8.7.5 Grifols Recent Developments
  43. 8.8 F. Hoffmann-La Roche
  44. 8.8.1 F. Hoffmann-La Roche Company Information
  45. 8.8.2 F. Hoffmann-La Roche Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Recent Developments
  49. 8.9 Dimension Therapeutics
  50. 8.9.1 Dimension Therapeutics Company Information
  51. 8.9.2 Dimension Therapeutics Business Overview
  52. 8.9.3 Dimension Therapeutics Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
  54. 8.9.5 Dimension Therapeutics Recent Developments
  55. 8.10 CSL Behring
  56. 8.10.1 CSL Behring Company Information
  57. 8.10.2 CSL Behring Business Overview
  58. 8.10.3 CSL Behring Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSL Behring Hemophilia Drugs Product Portfolio
  60. 8.10.5 CSL Behring Recent Developments
  61. 8.11 Catalyst Biosciences
  62. 8.11.1 Catalyst Biosciences Company Information
  63. 8.11.2 Catalyst Biosciences Business Overview
  64. 8.11.3 Catalyst Biosciences Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
  66. 8.11.5 Catalyst Biosciences Recent Developments
  67. 8.12 BioMarin
  68. 8.12.1 BioMarin Company Information
  69. 8.12.2 BioMarin Business Overview
  70. 8.12.3 BioMarin Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioMarin Hemophilia Drugs Product Portfolio
  72. 8.12.5 BioMarin Recent Developments
  73. 8.13 Baxalta
  74. 8.13.1 Baxalta Company Information
  75. 8.13.2 Baxalta Business Overview
  76. 8.13.3 Baxalta Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Baxalta Hemophilia Drugs Product Portfolio
  78. 8.13.5 Baxalta Recent Developments
  79. 8.14 Alnylam Pharmaceuticals
  80. 8.14.1 Alnylam Pharmaceuticals Company Information
  81. 8.14.2 Alnylam Pharmaceuticals Business Overview
  82. 8.14.3 Alnylam Pharmaceuticals Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
  84. 8.14.5 Alnylam Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst